PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Results of the GIANT trial reported at TCT 2013

Genetic profiling may provide clinical benefit by identifying heart attack patients that are resistant to blood thinners

2013-11-01
(Press-News.org) Contact information: Judy Romero
jromero@crg.org
Cardiovascular Research Foundation
Results of the GIANT trial reported at TCT 2013 Genetic profiling may provide clinical benefit by identifying heart attack patients that are resistant to blood thinners SAN FRANCISCO, CA – October 31, 2013 – According to a new study, genetic profiling of patients undergoing percutaneous coronary intervention (PCI) may help cardiology teams adjust treatment and improve ischemic outcomes for patients that do not properly metabolize thienopyridine blood thinning therapies such as clopidogrel.

Findings from the GIANT trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

The effectiveness of clopidogrel depends on activation to an active metabolite, principally via the CYP2C19 enzymatic pathway. Acute coronary syndrome patients that carry a CYP2C19 gene variant poorly metabolize the drug. These patients are known as slow responders and exhibit a higher one year risk of major ischemic events following PCI. Genetic tests can help identify a patient's CYP2C19 genotype, but it is unknown if on-line adjustment of thienopyridine therapy in the genetically slow-responder patient population may counteract this outcome.

The GIANT trial evaluated the clinical impact of CYP2C19 genetic profiling and compliance to an adjusted thienopyridine treatment. The primary endpoint was a composite of death, myocardial infarction, and stent thrombosis after one year in slow responder patients with appropriate therapy after genotyping, compared to non-slow responders.

The prospective, multicenter, single arm study enrolled 1,499 patients at the time of primary PCI (onset chest pain < 24 hours). Genetic profiling was performed within 48 hours after intervention to detect a loss of CYP2C19 gene function and identify a resistance to clopidogrel. Strong recommendations for treatment adjustment were sent to investigators when patients were identified as slow responders.

Dual antiplatelet therapy (DAPT) was prescribed for 12 months after PCI and one year follow up was performed in 96.4 percent of patients (n=1,445) including objective assessment of compliance. A total of 22 percent of patients (n=319) had a profile associated with a CYP2C19 loss of function, known as the slow responder group. The remaining patients constituted the control group.

In the slow responder group, 85 percent received an adjusted thienopyridine regimen after the release of the genetic profile. Within the slow responder group, the patients that did receive adjusted therapy experienced fewer adverse events compared to those that did not have adjusted therapy (3.3 percent vs. 15.6 percent, respectively) after one year. Further, the patients that received adjusted therapy experienced a similar rate of adverse events as the control group (3.3 percent vs. 3.04 percent). Poor compliance to treatment was objectively identified in 4.9 percent of patients at one year, and those patients experienced numerically more ischemic events.

"Results from the GIANT trial suggest that in patients with acute myocardial infarction treated with primary PCI, identification of a slow response to clopidogrel with subsequent adjustment of treatment leads to similar one year major ischemic event rates to patients with a favorable genetic profile to clopidogrel response," said lead investigator Bernard R. Chevalier, MD from L'Institut CardioVasculaire Paris-Sud in Massy, France.

"These findings may help determine alternative treatment strategies for patients identified as CYP2C19 poor metabolizers."

### The GIANT trial was funded by Biotronik. Dr. Chevalier reported receiving research grants/speaker fees or being a consultant for Abbott Vascular, Asahi, Astra Zeneca, AVI, Boston Scientific, Biotronik, Colibri, Cook, Cordis, Daichi-Sankyo, Eli-Lilly, Iroko, Medtronic, and Terumo. He is also currently a minor shareholder and director of CERC, a clinical research organization.

About CRF and TCT The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.


ELSE PRESS RELEASES FROM THIS DATE:

Percutaneous repair of valve leaks: A new treatment for patients at high risk of cardiac surgery

2013-11-01
Percutaneous repair of valve leaks: A new treatment for patients at high risk of cardiac surgery PCI repair can mitigate known risks that accompany increases in implanted valves MINNEAPOLIS, MN—October 31, 2013—A Paravalvular regurgitation, or leakage, ...

Results of the TATORT-NSTEMI trial presented at TCT 2013

2013-11-01
Results of the TATORT-NSTEMI trial presented at TCT 2013 Removing blood clots during PCI does not improve outcomes compared to standard angioplasty in patients with non-ST-elevation myocardial infarction SAN FRANCISCO, CA – OCTOBER 31, 2013 – According to a new study, ...

Results of the REPRISE II trial reported at TCT 2013

2013-11-01
Results of the REPRISE II trial reported at TCT 2013 Second generation transcatheter aortic valve shown to successfully address complications of TAVR SAN FRANCISCO, CA – THURSDAY OCTOBER 31, 2013 – In a clinical trial, a second-generation transcatheter aortic valve demonstrated ...

Experimental drug shows encouraging results in treating most common form of lung cancer

2013-11-01
Experimental drug shows encouraging results in treating most common form of lung cancer An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small ...

Oligomeric proanthocyanidin suppresses the death of retinal ganglion cells

2013-11-01
Oligomeric proanthocyanidin suppresses the death of retinal ganglion cells The death of retinal ganglion cells is a hallmark of many optic neurodegenerative diseases such as glaucoma and retinopathy. Oxidative stress is one of the major reasons to cause the ...

Can Aβ worsen cognitive impairment following cerebral ischemia-reperfusion injury?

2013-11-01
Can Aβ worsen cognitive impairment following cerebral ischemia-reperfusion injury? Amyloid β-peptide, a major component of senile plaques in Alzheimer's disease, has been impli-cated in neuronal cell death and cognitive impairment. Recently, studies ...

Low-frequency rTMS prevents chronic epileptic seizure

2013-11-01
Low-frequency rTMS prevents chronic epileptic seizure Although increasing evidence indicates that low-frequency repetitive transcranial magnetic stimulation (rTMS), an emerging technology for neural regulation, has antiepileptic effects, the mechanism remains unclear. ...

Exposure to cortisol-like medications before birth may contribute to emotional problems and brain changes

2013-11-01
Exposure to cortisol-like medications before birth may contribute to emotional problems and brain changes Reports new study in Biological Psychiatry Philadelphia, PA, October 31, 2013 – Neonatologists seem to perform miracles in the fight to support the survival of ...

JCI early table of contents for Nov. 1, 2013

2013-11-01
JCI early table of contents for Nov. 1, 2013 Liver tropism is key for B cell deletion immunotherapy Antibodies against the B cell surface protein CD20 have been used successfully to treat B cell-mediated autoimmune diseases and lymphomas. Antibody binding ...

Liver tropism is key for B cell deletion immunotherapy

2013-11-01
Liver tropism is key for B cell deletion immunotherapy Antibodies against the B cell surface protein CD20 have been used successfully to treat B cell-mediated autoimmune diseases and lymphomas. Antibody binding receptors, called Fc receptors, on other ...

LAST 30 PRESS RELEASES:

Salk scientist Joseph Ecker awarded McClintock Prize for Plant Genetics and Genome Studies

ADHD: Women are diagnosed five years later than men, despite symptoms appearing at the same age.

Power plants may emit more pollution during government shutdowns

Increasing pressures for conformity de-skilling and demotivating teachers, study warns

Researchers develop smarter menstrual product with potential for wearable health monitoring

Microwaves for energy-efficient chemical reactions

MXene current collectors could reduce size, improve recyclability of Li-ion batteries

Living near toxic sites linked to aggressive breast cancer

New discovery could open door to male birth control

Wirth elected Fellow of American Physical Society

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 10, 2025

Destined to melt

Attitudes, not income, drive energy savings at home

The playbook for perfect polaritons

‘Disease in a dish’ study of progressive MS finds critical role for unusual type of brain cell

Solar-powered method lights the way to a ‘de-fossilized’ chemical industry

Screen time linked to lower academic achievement among Ontario elementary students

One-year outcomes after traumatic brain injury and early extracranial surgery in the TRACK-TBI Study

Enduring outcomes of COVID-19 work absences on the US labor market

Affirmative action repeal and racial and ethnic diversity in us medical school admissions

Cancer progression illuminated by new multi-omics tool

Screen time and standardized academic achievement tests in elementary school

GLP-1RA order fills and out-of-pocket costs by race, ethnicity, and indication

Study finds HEPA purifiers alone may not be enough to reduce viral exposure in schools

UVA Health developing way to ID people at risk of dangerous lung scarring even before symptoms appear

How can we know when curing cancer causes myocarditis?

Male infertility in Indian men linked to lifestyle choices and hormonal imbalances

An acoustofluidic device for sample preparation and detection of small extracellular vesicles

The advent of nanotechnology has ushered in a transformative era for oncology, offering unprecedented capabilities for targeted drug delivery and controlled release. This paradigm shift enhances thera

A prototype LED as thin as wallpaper — that glows like the sun

[Press-News.org] Results of the GIANT trial reported at TCT 2013
Genetic profiling may provide clinical benefit by identifying heart attack patients that are resistant to blood thinners